EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease

Guoyi Yang, Amy M Mason, Dipender Gill, C Mary Schooling, Stephen Burgess

European Journal of Epidemiology · 2024

DOI: 10.1007/s10654-024-01141-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Epidemiology, 2024. Verfasst von Guoyi Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. yanggy@connect.hku.hk. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Cholesterol, LDL, Gallstones. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Data Research UK, British Heart Foundation, BHF Cambridge CRE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. Different plasma LDL-cholesterol lowering pathways may have distinct effects on biliary cholesterol and thereby gallstone disease risk. We conducted a Mendelian randomization (MR) study using data from the UK Biobank (30,547 gallstone disease cases/336,742 controls), FinnGen (34,461 cases/301,383 controls) and Biobank Japan (9,305 cases/168,253 controls). We first performed drug-target MR analyses substantiated by colocalization to investigate the effects of plasma LDL-cholesterol lowering therapies on gallstone disease risk. We then performed clustered MR analyses and pathway analyses to identify distinct mechanisms underlying the association of plasma LDL-cholesterol with gallstone disease risk. For a 1-standard deviation reduction in plasma LDL-cholesterol, genetic mimics of statins were associated with lower gallstone disease risk (odds ratio 0.72 [95% confidence interval 0.62, 0.83]), but genetic mimics of PCSK9 inhibitors and targeting apolipoprotein B were associated with higher risk (1.11 [1.03, 1.19] and 1.23 [1.13, 1.35]). The association for statins was supported by colocalization (posterior probability 98.7%). Clustered MR analyses identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease risk, with some evidence for ancestry-and sex-specific associations. Among variants lowering plasma LDL-cholesterol, those associated with lower gallstone disease risk were mapped to glycosphingolipid biosynthesis pathway, while those associated with higher risk were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters. This MR study provides genetic evidence that different plasma LDL-cholesterol lowering pathways have opposing effects on gallstone disease risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mendelian Randomization AnalysisCholesterol, LDLGallstonesHumansFemaleMaleMiddle AgedBiological Specimen BanksJapanHydroxymethylglutaryl-CoA Reductase InhibitorsUnited KingdomAgedAnticholesteremic Agents

Stichwörter der Autor:innen

Clustered Mendelian randomizationDrug-target Mendelian randomizationGallstone diseaseLDL-cholesterol

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic Agents

Autor:innen und Institutionen

  • School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. yanggy@connect.hku.hk.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. yanggy@connect.hku.hk.
  • British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Förderung

  • Health Data Research UK
  • British Heart Foundation
  • BHF Cambridge CRE
  • Medical Research Council
  • British Heart Foundation Centre of Research Excellence
  • Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship
  • EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant
  • Wellcome Trust

Zitieren

APA

Yang, G., Mason, A. M., Gill, D., Schooling, C. M., & Burgess, S. (2024). Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease. European Journal of Epidemiology. https://doi.org/10.1007/s10654-024-01141-5

Vancouver

Yang G, Mason AM, Gill D, Schooling CM, Burgess S. Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease. European Journal of Epidemiology. 2024. doi:10.1007/s10654-024-01141-5

BibTeX
@article{Yang2024,
  author = {Yang, Guoyi and Mason, Amy M and Gill, Dipender and Schooling, C Mary and Burgess, Stephen},
  title = {Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease},
  journal = {European Journal of Epidemiology},
  year = {2024},
  doi = {10.1007/s10654-024-01141-5}
}
Kostenlos starten →